Leverage one of Canada’s most research intensive institutes to advance your business objectives.

SickKids innovators are on the front lines of health innovation. Working with IP&C, industry partners can access the research and clinical innovation ecosystem at SickKids through:

Licensing
opportunities

Source from over 100 technologies across IP&C’s comprehensive Technology Portfolio.

Sponsored
research

Benefit from top-tier expertise in a variety of disciplines across SickKids Research Programs and clinical divisions to complement your research needs.

Start-up creation opportunities

Develop new start-up companies working in collaboration with SickKids innovators.

Areas of expertise

IP&C maintains a comprehensive intellectual property portfolio and has numerous research and clinical inventions available for licensing and development.

These technologies cover many areas of excellence at SickkKids and top market opportunities, including:

  • Anti-Infectives

  • Cardiovascular

  • Cystic Fibrosis

  • Developmental disorders

  • Diagnostics

  • Gene editing

  • Immunology

  • Medical devices

  • Neuromuscular disorders

  • Orphan and rare diseases

  • Paediatric oncology

  • Stem cells and regenerative medicine

SickKids start-ups

IP&C helps SickKids innovators turn breakthrough research innovation into companies with real impact.

  • Bedside Clinical Systems logo
  • CellAegis Devices logo
  • Gene 42 logo
  • HeadSoothe Nutraceuticals logo
  • OtoSim logo
  • Simulare Medical
  • ScarX Therapeutics logo
  • Reveille Inc. logo
  • ERAD Therapeutics logo

History of innovation at SickKids

From the invention of Pablum to the discovery of the cystic fibrosis gene, SickKids innovators have pushed the boundaries of medicine to help improve the lives of patients in Canada and around the globe. Be a part of innovation history at SickKids by partnering with IP&C.

1930

Invented Pablum, the first ready-to-use enriched baby cereal that saved thousands of children from death and disease

1963

Developed the Mustard surgical procedure to help correct heart problems in blue baby syndrome

1989

Discovered the Cystic Fibrosis gene, paving the path for individualized medicine

1993

Discovered the Wilson disease gene, allowing for better diagnosis and treatment of liver disease

2004

Discovered the phenomena of copy number variation (CNVs)

2010

Co-developed the Hemophilia Joint Health Score (HJHS) as a validated multi-item outcome measure for the assessment of joint health primarily designed for children with hemophilia aged 4 to 18 years old with mild joint impairment (e.g., treated with prophylaxis)

2017

Co-developed the Pediatric Ulcerative Colitis Activity Index (PUCAI) as a validated multi-item outcome measure of ulcerative colitis disease activity that meets the need for non-invasive testing of paediatric patients with ulcerative colitis

2019

Appointed first-ever Chair in Biomedical Informatics and Artificial Intelligence, the first of its kind at a Canadian children’s hospital